Transition Bio

Transition Bio leverages AI, machine learning, and microfluidics to develop novel therapeutics based on biomolecular condensates—organelles inside cells that contribute to diseases. It is initially focusing on oncology targets and intends to expand to other indications in future. 

The company’s proprietary drug discovery platform “Condensomics” is segregated into four different pillars: 1) PhaseScan, which screens and gathers data on the mechanisms of condensate modulations, which are reportedly unavailable elsewhere; 2) CelPhase for imaging and analytics; 3) PhaseSeq to identify best condensate targets by analyzing its effect on cellular processes; and 4) DeePhase for target prediction and in-silico drug discovery. 

Funding and financials

In June 2022, Transition Bio raised USD 50 million in a Series A funding round led by Northpond Ventures, with participation from big pharma player Bristol-Myers Squibb, among others. The funds were earmarked for advancing its drug discovery platform and exploring a variety of therapeutic areas and disease indications.